Beverly Lo, NP
Nurse Practitioner · Winston Salem, NCNPI 1649860487
Payments from drug & device makers
Across 250 payments — averaging $15.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$651
- Novo Nordisk$515
- Pfizer$365
- Lilly USA, LLC$269
- Collegium Pharmaceutical, Inc.$191
- AstraZeneca$150
- plus $2K from 31 others
What the payments were for
- Food & beverage$3,791100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 53 | $651 |
| Novo Nordisk | 40 | $515 |
| Pfizer | 29 | $365 |
| Lilly USA, LLC | 17 | $269 |
| Collegium Pharmaceutical, Inc. | 11 | $191 |
| AstraZeneca | 10 | $150 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $145 |
| Merck | 7 | $137 |
| Otsuka America Pharmaceutical, Inc. | 6 | $130 |
| Idorsia Pharmaceuticals US Inc | 7 | $112 |
| Daiichi Sankyo Inc. | 4 | $91 |
| Scilex Pharmaceuticals Inc. | 5 | $85 |
| Bayer | 5 | $78 |
| Sanofi-aventis U.S. LLC | 4 | $77 |
| Corium, LLC | 5 | $72 |
| GSK | 3 | $59 |
| Regeneron Healthcare Solutions, Inc. | 2 | $59 |
| Paratek Pharmaceuticals, Inc. | 4 | $55 |
| Amgen | 3 | $52 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $51 |
| Gilead | 2 | $50 |
| Shield Therapeutics Inc | 3 | $46 |
| Exact Sciences | 2 | $39 |
| Medtronic | 2 | $37 |
| Intercept Pharmaceuticals, Inc. | 2 | $28 |
| Vanda Pharmaceuticals Inc. | 2 | $28 |
| Indivior Inc. | 1 | $27 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $26 |
| Novartis | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| Alkermes, Inc. | 1 | $19 |
| Tris Pharma Inc | 1 | $19 |
| Forte Bio-pharma LLC | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $15 |
How this compares
$3,791 in reported general payments places this provider in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 58 | $61,291 |
| OzempicSemaglutide | 56 | $56,549 |
| TrulicityDulaglutide | 37 | $36,146 |
| RybelsusSemaglutide | 17 | $25,747 |
| FarxigaDapagliflozin Propanediol | 22 | $23,890 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $15,947 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 82 | $10,963 |
| ZtlidoLidocaine | 27 | $9,786 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $5,265 |
| Dexlansoprazole DrDexlansoprazole | 16 | $4,371 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 135 | $4,124 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 115 | $3,111 |
| Naloxone Hcl | 36 | $2,269 |
| Pregabalin | 41 | $1,967 |
| Oxycodone Hcl | 107 | $1,805 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $269 | $97,43795 claims |
| Novo NordiskOzempic, Rybelsus | $515 | $82,29673 claims |
| AstraZenecaFarxiga, Symbicort | $150 | $29,15538 claims |
| GSKTrelegy Ellipta | $59 | $15,94712 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine | $18 | $12,09193 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $85 | $9,78627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.
Other nurse practitioner in Winston Salem
- Olivia OgburnWinston Salem$70K
- Amy MitchellWinston Salem$33K
- Mary SandsWinston Salem$32K
- Ladonna CookWinston Salem$23K
- Gillian WinterWinston Salem$18K
- Christine ZdebWinston Salem$15K
- Sandrivette JohnsonRaleigh$573K
- Skyler RogersPinehurst$174K
- Jamie DinerDurham$170K
- Ayeshia WrightMocksville$145K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.